Story at a glance
- The Trump administration has identified five pharmaceutical companies likely to develop a vaccine by the end of the year.
- These five finalists will have access to greater government funding and resources.
Five pharmaceutical companies have been selected as the most likely candidates to develop a coronavirus vaccine by the Trump administration, the New York Times reports.
The administration is currently aiming for the development of a vaccine within 12 to 18 months, a goal Anthony Fauci, the lead infectious disease expert on the White House Coronavirus Task Force, calls “aspiration, but…certainly doable.”
America is changing FASTER THAN EVER. Add Changing America to your Facebook and Twitter
The five companies include Moderna, the partnership between Oxford University and AstraZeneca, Johnson & Johnson, Merck & Co. and Pfizer. The Times reports that each company has a different approach regarding vaccine development.
The announcement of the decision will reportedly be made at the White House in the coming weeks, government sources tell the Times.
Moderna, Johnson & Johnson and Oxford-AstraZeneca have received a cumulative $2.2 billion in federal funding to support their research and development. By being selected as the top five most promising candidates, all five companies will have access to additional government funding, financial and logistical resources for manufacturing and clinical trials.
WHAT YOU NEED TO KNOW ABOUT CORONAVIRUS RIGHT NOW
HERE ARE THE 6 WAYS THE CORONAVIRUS PANDEMIC COULD END
COUNTRIES LED BY WOMEN HAVE FARED BETTER AGAINST CORONAVIRUS. WHY?
6 FEET OF DISTANCE MAY NOT BE ENOUGH TO STOP SPREAD OF CORONAVIRUS
EXPERTS: 90% OF CORONAVIRUS DEATHS COULD HAVE BEEN AVOIDED
HERE’S WHEN IT’S SAFE FOR YOUR STATE TO REOPEN
Published on Jun 03,2020